Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy

NCT05675319 is registered in ClinicalTrials.gov with Universitätsklinikum Hamburg-Eppendorf as lead sponsor.

NCT NCT05675319
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05675319 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy
Lead sponsor
Universitätsklinikum Hamburg-Eppendorf
Phase
Phase 3
Overall status
Terminated
Start date
March 3, 2023
Completion date
March 21, 2025
Enrollment
28 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma